Evidence map›Paper›PMID 33708425›Full record

ArticleJournal of gastrointestinal oncology2021

Xiaoyu He, Guohua Cheng, Feng Xiao, Lei Zhang, Gang Jin, Xin Zhao, Ying Liu, Juan Liang, Yarong Li, Zhaoyu Liu and 12 more

Open access · diamondAbstract read
In one paragraph

Article in Journal of gastrointestinal oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Xiaoyu HeDepartment of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Guohua ChengDepartment of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Feng XiaoDepartment of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Lei ZhangDepartment of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Gang JinDepartment of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Xin ZhaoDepartment of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Ying LiuDepartment of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Juan LiangDepartment of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Yarong LiDepartment of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Zhaoyu LiuDepartment of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Qiang YuanDepartment of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Hongwei RenDepartment of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Qilong WuDepartment of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Jinrong WuDepartment of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Lili XueDepartment of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Jing FengDepartment of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Zhihui WangDepartment of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Yueming XingDepartment of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Wei WuDepartment of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Zheng LiDepartment of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Dong WeiDepartment of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Xiang SongDepartment of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Second Hospital of Shanxi Medical University · CNShanxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPolyps may develop into colorectal cancer (CRC) after 10-20 years. The occurrence of polyps and tumors caused by somatic gene mutations is considered a main pathogenesis of CRC. Among all general patients with polyps or CRC, some had adenoma of varying degrees that were consistent with familial colorectal adenomas. A patient with CRC (the propositus) and his brothers and sister, all of whom had varying degrees of colorectal polyps showed different adenomas with different members in a family.

methodsIn the present study, a total of 9 family members were investigated, and a family tree was drawn. Genomic DNA was extracted from peripheral venous blood samples from family members, and whole-exome sequencing (WES) and Sanger sequencing were performed on the DNA samples. The result of WES was compared with compared directly to the reference genome (hg19) with Burrows-Wheeler Aligner, which is as control group from.

resultsWe identified a base substitution in the

conclusionsThe mutation of the

Indexed as

bioinformatics analysiscolorectal cancer (CRC)colorectal polypmiR-4477bmutationphosphoinositide 3-kinase

Identifiers

PMID33708425
PMCPMC7944151
OpenAlexW3135493056

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.